Willoughby Scott B. 4
Accession 0001877368-26-000002
Filed
Jan 25, 7:00 PM ET
Accepted
Jan 26, 4:12 PM ET
Size
6.2 KB
Accession
0001877368-26-000002
Research Summary
AI-generated summary of this filing
Sangamo (SGMO) Scott B. Willoughby Surrenders 36,676 Shares for Taxes
What Happened
Scott B. Willoughby, SVP, Chief Legal Officer and Secretary of Sangamo Therapeutics (SGMO), surrendered 36,676 shares on January 22, 2026 to satisfy mandatory tax withholding related to RSUs that vested that day. The withholding was reported as a disposition (code F) at $0.3985/share (company closing price), totaling approximately $14,615. This was a tax-withholding transaction — not an open-market sale or discretionary trade.
Key Details
- Transaction date and price: January 22, 2026; shares withheld at $0.3985 per share (reported as $0.40 rounding), total ≈ $14,615.
- Transaction type: Code F — mandatory tax withholding (surrender of vested RSU shares to the issuer).
- Footnote: The shares surrendered represented part of the RSU vesting on Jan 22, 2026; the surrender was automatic for tax purposes and not a market sale.
- Vesting context: Footnote notes the reporting person’s RSU schedule includes 52,387 shares from the Jan 22, 2024 RSU vesting installment, plus additional unvested RSUs from 2023 and 2025 grants (see filing).
- Filing timeliness: Form 4 filed Jan 26, 2026 (timely within required reporting window).
Context: This was a routine tax-withholding disposition tied to RSU vesting. Such transactions are common when companies allow employees to surrender vested shares to cover taxes; they do not necessarily indicate a change in insider sentiment about the company.
Insider Transaction Report
- Tax Payment
Common Stock
[F1][F2]2026-01-22$0.40/sh−36,676$14,615→ 665,410 total
Footnotes (2)
- [F1]Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on January 22, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2026 of $0.3985/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
- [F2]Includes: 52,387 shares from the January 22, 2026 vesting installment of the Reporting Person's January 22, 2024 RSU grant, (b) 4,008 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Signature
Documents
Issuer
SANGAMO THERAPEUTICS, INC
CIK 0001001233
Related Parties
1- filerCIK 0001877368
Filing Metadata
- Form type
- 4
- Filed
- Jan 25, 7:00 PM ET
- Accepted
- Jan 26, 4:12 PM ET
- Size
- 6.2 KB